We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSIG Regulatory News (SHI)

Share Price Information for SIG (SHI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.00
Bid: 26.80
Ask: 27.05
Change: 0.00 (0.00%)
Spread: 0.25 (0.933%)
Open: 27.05
High: 27.35
Low: 26.80
Prev. Close: 27.00
SHI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Admission of New Ordinary Shares

10 Jul 2020 08:04

RNS Number : 6025S
SIG PLC
09 July 2020
 

 

 

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, ITS TERRITORIES AND POSSESSIONS, CANADA, JAPAN, SOUTH AFRICA, MALAYSIA, NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT. NOTHING HEREIN SHALL CONSTITUTE AN OFFERING OF SHARES. NOTHING IN THIS ANNOUNCEMENT SHOULD BE INTERPRETED AS A TERM OR CONDITION OF THE NEW SHARE ISSUE. ANY DECISION TO PURCHASE, SUBSCRIBE FOR, OTHERWISE ACQUIRE, SELL OR OTHERWISE DISPOSE OF SHARES MUST BE MADE ONLY ON THE BASIS OF THE INFORMATION CONTAINED IN AND INCORPORATED BY REFERENCE INTO THE PROSPECTUS. COPIES OF THE PROSPECTUS ARE AVAILABLE AT WWW.SIGPLC.COM.

 

10 July 2020

SIG plc

(the "Company")

 

Admission of New Ordinary Shares

 

The Company today announces that, pursuant to the CD&R Investment, the Firm Placing and Placing and Open Offer and the Directors and Senior Management Subscription announced on 19 June 2020, 589,999,995 New Ordinary Shares will be admitted to listing on the premium listing segment of the Official List of the Financial Conduct Authority and will be admitted to trading on the London Stock Exchange plc's Main Market for listed securities at 8.00 a.m. today.

 

All capitalised terms in this announcement have the meaning given to them in the combined circular and prospectus dated 19 June 2020 (the "Prospectus"), unless otherwise defined in this announcement.

 

LEI: 213800VDC1BKJEZ8PV53

 

 

Enquiries

 

SIG plc

Andrew Allner, Chairman +44 (0) 114 285 6300

Steve Francis, Chief Executive Officer +44 (0) 114 285 6300

Ian Ashton, Chief Financial Officer +44 (0) 114 285 6300

 

Lazard - Lead Financial Adviser

Cyrus Kapadia / Vasco Litchfield / Nick Fowler +44 (0) 20 7187 2000

 

Jefferies International Limited - Financial Adviser, Joint Sponsor & Joint Broker

Ed Matthews / Philip Noblet / Lee Morton / Will Soutar +44 (0) 20 7029 8000

 

Peel Hunt LLP - Financial Adviser, Joint Sponsor & Joint Broker

Charles Batten / Nicholas How / Sam Cann +44 (0) 20 7418 8900

 

FTI Consulting

Richard Mountain / Susanne Yule +44 (0) 20 3727 1340

 

Important notices

Lazard & Co., Limited (Lazard) and each of Jefferies International Limited (Jefferies) and Peel Hunt LLP (Peel Hunt) (together, in the case only of Jefferies and Peel Hunt, the Joint Bookrunners), which are each authorised and regulated in the UK by the FCA, are each acting exclusively for SIG plc and no one else in connection with the contents of this announcement, the Capital Raise or any other matters referred to in this announcement and will not regard any other person as a client in relation to the Capital Raise or any other matters referred to in this announcement and will not be responsible to anyone for providing the protections afforded to their clients nor for giving advice to any other person in relation to the contents of this announcement, the Capital Raise or any other matter or arrangement referred to in this announcement. Neither Lazard nor the Joint Bookrunners are responsible for the contents of this announcement.

This announcement has been issued by and is the sole responsibility of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by either Joint Bookrunner, Lazard or by any of their respective affiliates, directors, employees, advisers or agents as to, or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

Neither this announcement nor any copy of it nor the information contained in it and any related materials is for publication, distribution or release, in whole or in part, directly or indirectly, in or into or from the United States (including its territories and possessions, any State of the United States and the District of Columbia) (subject to certain restrictions), Australia, its territories and possessions, Canada, Japan, South Africa, Malaysia, New Zealand or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

The distribution of this announcement and the offering of the New Ordinary Shares may be restricted by law in certain jurisdictions.

The New Ordinary Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under any securities laws of any state or other jurisdiction of the United States. The New Ordinary Shares may not be offered, sold, taken up, exercised, resold, transferred or delivered, directly or indirectly, into or within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There will be no public offer of the New Ordinary Shares in the United States.

The New Ordinary Shares to be issued or sold pursuant to the Firm Placing and Placing and Open Offer will not be admitted to trading on any stock exchange other than the London Stock Exchange.

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this announcement.

Information to Distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (MiFID II); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the MiFID II Product Governance Requirements), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the New Ordinary Shares to be issued in the Capital Raise have been subject to a product approval process, which has determined that the New Ordinary Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the Target Market Assessment). Notwithstanding the Target Market Assessment, distributors should note that: the price of the New Ordinary Shares may decline and investors could lose all or part of their investment; the New Ordinary Shares to be issued in the Capital Raise provide no guaranteed income and no capital protection; and an investment in the New Ordinary Shares to be issued in the Capital Raise is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Capital Raise. Furthermore, it is noted that, notwithstanding the Target Market Assessment, Jefferies and Peel Hunt will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to, the New Ordinary Shares.

Each distributor is responsible for undertaking its own Target Market Assessment in respect of the New Ordinary Shares and determining appropriate distribution channels.

Unless the context otherwise requires, all references to time are to London time.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
LISRLMLTMTTMBFM
Date   Source Headline
12th Apr 20244:01 pmRNSDirector/PDMR Shareholding
4th Apr 202410:12 amRNSDirector/PDMR Shareholding
25th Mar 202410:21 amRNSNotice of AGM
22nd Mar 202410:30 amRNSDirector/PDMR Shareholding
22nd Mar 202410:12 amRNSDirector/PDMR Shareholding
5th Mar 202412:14 pmRNSAnnual Financial Report
5th Mar 20247:00 amRNSFull year results for year ended 31 December 2023
9th Jan 20247:00 amRNS2023 Full Year Trading Update
1st Dec 20235:42 pmRNSDirector/PDMR Shareholding
23rd Nov 20239:00 amRNSCapital Markets Event
13th Nov 20239:00 amRNSNotice of Capital Markets Event
13th Oct 20233:51 pmRNSHolding(s) in Company
12th Oct 20237:00 amRNSQ3 Trading Update
25th Sep 20233:56 pmRNSDirectorate Change
9th Aug 20234:58 pmRNSHolding(s) in Company
8th Aug 20237:00 amRNSHalf-year Report
12th Jul 20234:26 pmRNSHolding(s) in Company
11th Jul 20234:06 pmRNSHolding(s) in Company
11th Jul 202310:58 amRNSHolding(s) in Company
10th Jul 202311:09 amRNSHolding(s) in Company
5th Jul 20233:15 pmRNSHolding(s) in Company
5th Jul 20237:00 amRNSH1 Trading Update
4th May 20232:32 pmRNSResult of AGM
4th May 20237:00 amRNSTrading Update
31st Mar 202312:47 pmRNSHolding(s) in Company
27th Mar 202310:30 amRNSNotice of AGM
13th Mar 20233:49 pmRNSDirector/PDMR Shareholding
13th Mar 20233:39 pmRNSDirector/PDMR Shareholding
13th Mar 202310:36 amRNSHolding(s) in Company
9th Mar 20237:00 amRNSDirector/PDMR Shareholding
8th Mar 20231:20 pmRNSAnnual Financial Report
8th Mar 20237:01 amRNSDirectorate Changes
8th Mar 20237:00 amRNSFull year results for the year ended 31 Dec 2022
27th Feb 202311:20 amRNSDirector Declaration
1st Feb 20237:00 amRNSDirectorate Change
10th Jan 20237:00 amRNS2022 Full Year Trading Update
16th Dec 20228:04 amRNSDirector Declaration
15th Sep 202210:49 amRNSDirectorate Changes
13th Sep 20224:59 pmRNSDirector/PDMR Shareholding
8th Sep 20227:00 amRNSCEO Steve Francis to be succeeded by Gavin Slark
9th Aug 20227:00 amRNSHalf-year Report
25th Jul 20227:00 amRNSAcquisition of Miers Construction Products Limited
1st Jul 20229:38 amRNSNotice of Half Year Results
22nd Jun 20229:53 amRNSChange of Adviser
12th May 20226:11 pmRNSResult of AGM
12th May 20222:52 pmRNSResult of AGM
29th Apr 20227:00 amRNSTrading Update
12th Apr 20223:21 pmRNSDirector/PDMR Shareholding
8th Apr 20223:28 pmRNSDirector/PDMR Shareholding
8th Apr 20223:25 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.